Copeland Capital Management LLC Increases Stake in LeMaitre Vascular, Signaling Confidence in Company’s Prospects

☀️Trending News

LEMAITRE ($NASDAQ:LMAT): LeMaitre Vascular, Inc. is a publicly traded medical device company that specializes in the development and marketing of peripheral vascular devices and implants. LeMaitre Vascular’s products are used by clinicians to treat peripheral vascular disease, which includes the diagnosis and treatment of arterial and venous diseases. Copeland Capital Management LLC, a global investment advisory firm, recently announced that it has increased its stake in LeMaitre Vascular. The decision to increase their stake is seen as a vote of confidence in the company’s prospects. The company has experienced strong sales growth over the past year and is well-positioned to capitalize on the growing demand for its products.

As such, Copeland Capital Management believes that the company is an attractive investment opportunity. The increased stake in LeMaitre Vascular is viewed as a positive indicator of the company’s future growth and success. With strong fundamentals and a growing market share, the outlook for the company is looking bright. As such, Copeland Capital Management’s decision to increase their stake appears to be a good one and should provide investors with further confidence in the company’s long-term prospects.

Price History

This indicates that the company is confident in LeMaitre Vascular‘s prospects. In response to the news, the stock opened at $67.1 and closed at the same price, indicating investors were pleased with Copeland’s move. Despite a slight dip of 0.4% from the prior closing price of $67.4, LeMaitre Vascular’s stock still performed well on the day. This signals that Copeland’s decision has instilled investors with confidence in the company’s future. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Lemaitre Vascular. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Lemaitre Vascular. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Lemaitre Vascular. More…

Key Ratios Snapshot

Some of the financial key ratios for Lemaitre Vascular are shown below. More…

Analysis

At GoodWhale, we recently conducted an analysis of LEMAITRE VASCULAR‘s wellbeing. We found that the company has a medium risk rating in terms of financial and business aspects. This means that while the company is relatively stable, there may be certain risks associated with investing in it. We detected one risk warning in the balance sheet of LEMAITRE VASCULAR. This warning may indicate that the company is at greater risk than initially expected. To find out more, we recommend registering on our website, goodwhale.com. There you can find further details about the risk warning and other risks associated with this company. We want to ensure that all our customers make educated investment decisions and understand the risks associated with their investments. More…

Peers

It focuses on the development, manufacture and marketing of minimally invasive products for the treatment of peripheral vascular diseases. The company operates through two segments, Direct and OEM. The Direct segment offers proprietary products to hospitals and other medical institutions through direct sales force. The OEM segment provides stents and other products to Original Equipment Manufacturers (OEMs) for sale under their own brands. LeMaitre’s competitors include Atrion Corp, Implanet SA, Vycor Medical Inc.

– Atrion Corp ($NASDAQ:ATRI)

Atrion Corporation is a medical device company that develops, manufactures and markets products primarily for use in cardiac and ophthalmic surgery. The company’s products include Cardiax, a cannula used in cardiac surgery; Ophthalmic products, including the HydroVue and Glaucoma Shunt systems to treat glaucoma; and PerQCat, a catheter used in urology procedures.

– Implanet SA ($OTCPK:IMPZY)

Implanet SA is a French company specializing in the design and manufacture of medical implants for the treatment of orthopedic pathologies. The company’s products are used in the treatment of various conditions, including osteoarthritis, degenerative disc disease, scoliosis, and deformities of the hip, knee, and shoulder. As of 2022, Implanet SA had a market capitalization of 3.88 million euros and a return on equity of -114.56%. The company’s products are sold in over 50 countries worldwide and its customers include some of the world’s leading orthopedic surgeons and hospitals.

– Vycor Medical Inc ($OTCPK:VYCO)

Vycor Medical Inc is a medical device company that specializes in the development and commercialization of minimally invasive products for neurosurgery. The company’s products are designed to provide surgeons with improved access and visualization during surgery, while minimizing tissue damage and surgical time. Vycor Medical’s products are sold in over 30 countries worldwide.

As of 2022, Vycor Medical Inc had a market capitalization of 3.17 million and a return on equity of 6.36%. The company’s products are used in a variety of neurosurgical procedures, including brain surgery, spinal surgery, and skull-base surgery.

Summary

Copeland Capital Management LLC recently increased their stake in LeMaitre Vascular, Inc. (LEMAITRE), signaling confidence in the company’s performance. Analysts rate LEMAITRE as a “Buy”, noting that the company has a low debt-to-equity ratio and is well-positioned to benefit from the current market environment. The company’s dividend yield is also attractive, providing investors with a steady stream of income. Overall, LEMAITRE is a promising investment for investors looking to increase their portfolio returns.